Actemra (tocilizumab) generates over $4 billion in annual global sales for Genentech/Roche, making it one of the highest-revenue biologic drugs in rheumatology and beyond. An Actemra biosimilar would offer meaningful cost relief for patients treating rheumatoid arthritis, giant cell arteritis, and other inflammatory conditions currently managed with this expensive biologic therapy. With key patents expiring and multiple manufacturers pursuing development, biosimilar competition is on the horizon.
What Is Actemra and What Does It Treat?
Actemra is a monoclonal antibody that blocks interleukin-6 (IL-6) receptors, inhibiting a key inflammatory pathway involved in multiple autoimmune and inflammatory conditions. The FDA first approved Actemra in January 2010 for moderate-to-severe rheumatoid arthritis in adults who had inadequate responses to other disease-modifying treatments.
Subsequent approvals expanded Actemra’s indications to include giant cell arteritis (2017), polyarticular and systemic juvenile idiopathic arthritis, and cytokine release syndrome (CRS). During the COVID-19 pandemic, Actemra received an Emergency Use Authorization in June 2021 for hospitalized adults requiring supplemental oxygen, based on evidence that IL-6 inhibition could reduce mortality in severe COVID-19 cases.
Actemra is available in both intravenous and subcutaneous formulations. The IV formulation is administered every four weeks in a clinical setting, while the subcutaneous injection can be self-administered weekly or every other week. Annual treatment costs for Actemra range from $20,000 to $36,000 depending on the formulation, dosing schedule, and indication.
Actemra Patent Expiration Timeline
Roche and Genentech hold multiple patents covering tocilizumab, including composition-of-matter patents, formulation patents, and method-of-use patents. Key composition patents have expired or are set to expire, opening the door for Actemra biosimilar development and regulatory submission.
Patent litigation between Roche and prospective biosimilar manufacturers has followed the pattern seen with other major biologics, involving the “patent dance” process outlined in the Biologics Price Competition and Innovation Act (BPCIA). Settlement agreements between the parties typically establish specific launch dates for biosimilar market entry. Understanding how drug patents work is essential for tracking when biosimilar competition will arrive.
Biosimilar Tocilizumab in Development
Several pharmaceutical companies have initiated biosimilar development programs for tocilizumab. These programs involve the full spectrum of biosimilar development activities, including extensive analytical characterization comparing the biosimilar to the reference product, preclinical pharmacology and toxicology studies, and Phase I and Phase III clinical trials.
Companies including Biogen, Samsung Bioepis, and Fresenius Kabi have reported progress on tocilizumab biosimilar programs. Clinical trials for these candidates have typically enrolled patients with rheumatoid arthritis, using standard endpoints such as ACR20 response rates (the proportion of patients achieving at least 20 percent improvement in American College of Rheumatology criteria) to demonstrate equivalent efficacy.
The regulatory pathway for these products follows the framework established for other biosimilar approvals. For a comprehensive overview of how this process works, see our article on what biosimilars are and how they reach the market.
Expected Cost Savings from Actemra Biosimilars
Based on experience from other biosimilar markets, patients and the healthcare system can expect meaningful cost reductions once Actemra biosimilar competition begins. Initial biosimilar launches typically offer discounts of 15 to 35 percent, with deeper discounts developing as additional competitors enter the market.
The biosimilar Humira market provides an instructive precedent. Adalimumab biosimilar prices eventually dropped by 80 percent or more as competition intensified. While the tocilizumab market may follow a different trajectory depending on the number of competitors and payer dynamics, substantial savings are anticipated.
For a patient currently paying $30,000 per year for Actemra, a 30 percent biosimilar discount would save $9,000 annually. These savings could be even larger for patients with coinsurance obligations on specialty drugs, where out-of-pocket costs are calculated as a percentage of the drug’s list price. Price comparison tools like GoodRx will be valuable resources for patients evaluating biosimilar options once they become available.
Safety Considerations for Tocilizumab Biosimilars
The FDA requires that all biosimilars demonstrate no clinically meaningful differences from the reference product in safety, efficacy, and immunogenicity. Tocilizumab carries specific safety considerations related to its mechanism of action, including increased risk of serious infections, elevated liver enzymes, changes in lipid profiles, and reduced neutrophil counts.
Clinical trials for tocilizumab biosimilars evaluate these safety endpoints alongside efficacy measures. Data published from Phase III studies have shown comparable adverse event rates between biosimilar candidates and the reference Actemra product. Post-marketing surveillance requirements ensure ongoing safety monitoring after approval.
One unique consideration for tocilizumab biosimilars involves the drug’s known effect on C-reactive protein (CRP), a common inflammation marker. Because tocilizumab suppresses CRP production, both the reference product and biosimilars can mask signs of infection. This pharmacological effect applies equally to biosimilar versions and does not represent a safety difference between the products.
How Biosimilar Competition Affects the IL-6 Inhibitor Market
Actemra is not the only IL-6 pathway inhibitor on the market. Kevzara (sarilumab), developed by Sanofi and Regeneron, targets the IL-6 receptor through a different antibody. The competitive dynamics between Actemra biosimilars and existing brand alternatives will influence pricing, formulary decisions, and prescribing patterns across the entire IL-6 inhibitor category.
Payers and pharmacy benefit managers (PBMs) will evaluate the relative value of biosimilar tocilizumab against other treatment options, considering both clinical evidence and cost. This competition, combined with biosimilar market entry, could drive down costs across the category and expand access for patients who might otherwise be unable to afford IL-6 inhibitor therapy.
Preparing for the Transition
If you currently take Actemra, proactive planning can help you take advantage of biosimilar options as they become available. Discuss biosimilar readiness with your rheumatologist or prescribing physician. They can provide perspective on the clinical evidence supporting biosimilar tocilizumab and help you evaluate whether a switch would be appropriate for your situation.
Contact your insurance provider to understand how your plan is likely to handle biosimilar formulary placement. Many payers have established policies favoring biosimilars through preferred tier placement, step therapy requirements, or financial incentives for switching. Knowing your plan’s approach in advance helps you prepare for potential formulary changes.
Frequently Asked Questions
When will Actemra biosimilars be available?
Multiple tocilizumab biosimilar programs are in advanced development, with FDA submissions and approvals expected in the mid-2020s. Specific launch dates depend on patent settlement terms, FDA review timelines, and manufacturing readiness. Check with your healthcare provider for the most current information on available options.
Will an Actemra biosimilar work the same way?
Yes. An FDA-approved biosimilar must demonstrate no clinically meaningful differences from the reference product in safety, efficacy, and immunogenicity. Clinical trials for tocilizumab biosimilars are designed to confirm equivalent performance in treating conditions like rheumatoid arthritis. For more on how biosimilars compare to other drug categories, see our guide on biosimilar vs generic differences.
Can I switch from Actemra to a biosimilar mid-treatment?
Yes, with physician guidance. Switching studies for biosimilars across multiple drug categories have consistently shown that transitioning from a reference product to a biosimilar does not increase the risk of adverse events or reduce efficacy. Your physician should evaluate your disease stability and treatment response before recommending a switch.
Will both IV and subcutaneous Actemra biosimilars be available?
Biosimilar manufacturers may choose to develop one or both formulations. The initial biosimilar offerings may focus on the IV formulation, with subcutaneous versions following depending on regulatory strategy and market demand. Check with your physician about which formulations are available in your area.
Looking Ahead at Tocilizumab Affordability
The development of Actemra biosimilar alternatives represents an important step toward more affordable access to IL-6 inhibitor therapy. For patients managing chronic inflammatory conditions, the arrival of biosimilar competition could reduce annual treatment costs by thousands of dollars. Stay engaged with your healthcare team, monitor biosimilar approvals through FDA.gov, and explore all available options for managing your healthcare costs as the competitive landscape evolves.